[{"NetIncomeLoss_1_Q1_USD":-53867000.0,"OperatingLeaseLiability_0_Q1_USD":32298000.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0_Q1_USD":19.31,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q1_USD":219346000.0,"AccruedLiabilitiesCurrent_0_Q1_USD":46467000.0,"InventoryFinishedGoodsNetOfReserves_0_Q1_USD":3748000.0,"BusinessCombinationContingentConsiderationLiability_0_Q1_USD":71300000.0,"LeaseIncentiveReceivable_0_Q1_USD":3247000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-262000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-105706000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":194255000.0,"LiabilitiesFairValueDisclosure_0_Q1_USD":71300000.0,"InterestIncomeExpenseNonoperatingNet_1_Q1_USD":-5321000.0,"Liabilities_0_Q1_USD":401356000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":149000.0,"AssetsCurrent_0_Q1_USD":565040000.0,"OperatingLeaseExpense_1_Q1_USD":1200000.0,"OtherNoncashIncomeExpense_1_Q1_USD":-375000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_1_Q1_USD":248835000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":36778000.0,"CostOfGoodsAndServicesSold_1_Q1_USD":1645000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":17979101.0,"AccruedSalariesCurrent_0_Q1_USD":9927000.0,"InventoryValuationReserves_0_Q1_USD":3500000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q1_USD":7479000.0,"ConvertibleDebtNoncurrent_0_Q1_USD":218076000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q1_USD":6200000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q1_USD":-463000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q1_USD":6386000.0,"ForeignCurrencyTransactionGainLossRealized_1_Q1_USD":1103000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":1002687000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":148232000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q1_USD":45561000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0_Q1_USD":149000.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q1_USD":117176000.0,"EarningsPerShareBasic_1_Q1_USD":-0.96,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1_Q1_USD":152400000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":-113000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1_Q1_USD":-463000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":56268508.0,"AssetsFairValueDisclosure_0_Q1_USD":520871000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":-1093000.0,"AccountsReceivableNetCurrent_0_Q1_USD":13066000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":313000.0,"CommonStockValue_0_Q1_USD":6000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":31206000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0_Q1_USD":0.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":-4443000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":6074000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":-788000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":195753000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_0_Q1_USD":149000.0,"PaymentForContingentConsiderationLiabilityFinancingActivities_1_Q1_USD":732000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1_Q1_USD":-1825000.0,"CostsAndExpenses_1_Q1_USD":94956000.0,"NumberOfBusinessesAcquired_1_Q1_business":2.0,"IncreaseDecreaseInInventories_1_Q1_USD":63000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-53227000.0,"AmortizationOfIntangibleAssets_1_Q1_USD":5952000.0,"OtherAssetsNoncurrent_0_Q1_USD":35030000.0,"StockGrantedDuringPeriodValueSharebasedCompensationGross_1_Q1_USD":2755000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1_Q1_USD":152399000.0,"CommonStockSharesIssued_0_Q1_shares":60435730.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q1_USD":372639000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-639742000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":63460000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":-2851000.0,"CommonStockSharesOutstanding_0_Q1_shares":60435730.0,"EarningsPerShareDiluted_1_Q1_USD":-0.96,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":392000.0,"Goodwill_0_Q1_USD":936000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-53554000.0,"TemporaryEquityForeignCurrencyTranslationAdjustments_1_Q1_USD":1103000.0,"InterestIncomeExpenseNet_1_Q1_USD":409000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-26474000.0,"InventoryRawMaterialsNetOfReserves_0_Q1_USD":3435000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":56268508.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q1_shares":5900000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q1_USD":6020000.0,"AccountsPayableCurrent_0_Q1_USD":15008000.0,"NonoperatingIncomeExpense_1_Q1_USD":-6005000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":148232000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":6747000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":2755000.0,"IncreaseDecreaseInOtherOperatingAssets_1_Q1_USD":726000.0,"AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1_Q1_USD":12200000.0,"PaymentsToAcquireIntangibleAssets_1_Q1_USD":4775000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q1_USD":214000.0,"FiniteLivedIntangibleAssetsNet_0_Q1_USD":151342000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0_Q1_USD":219346000.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":11697000.0,"LiabilitiesCurrent_0_Q1_USD":85013000.0,"AmortizationOfFinancingCostsAndDiscounts_1_Q1_USD":2737000.0,"IncreaseDecreaseInOtherOperatingLiabilities_1_Q1_USD":23000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":-177000.0,"Assets_0_Q1_USD":764045000.0,"ShareBasedCompensation_1_Q1_USD":7694000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":25038000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"ConvertibleDebtFairValueDisclosures_0_Q1_USD":281900000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q1_USD":10016000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q1_USD":6578000.0,"CommonStockSharesAuthorized_0_Q1_shares":100000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":47407000.0,"OperatingIncomeLoss_1_Q1_USD":-47549000.0,"DebtSecuritiesAvailableForSaleAmortizedCostCurrent_0_Q1_USD":372396000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q1_USD":282777000.0,"InventoryNet_0_Q1_USD":7183000.0,"IncreaseDecreaseInIncomeTaxesReceivable_1_Q1_USD":-238000.0,"IncomeTaxReceivable_0_Q1_USD":17173000.0,"FiniteLivedIntangibleAssetsGross_0_Q1_USD":268518000.0,"PreferredStockValue_0_Q1_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":764045000.0,"PreferredStockSharesAuthorized_0_Q1_shares":20000000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":7694000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0_Q1_USD":0.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":1092000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":43167000.0,"OtherLiabilitiesCurrent_0_Q1_USD":7338000.0,"StockholdersEquity_0_Q1_USD":362689000.0,"DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_0_Q1_USD":0.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":4495000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q1_USD":372396000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":47946000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q1_USD":1842000.0,"Ticker":"TVTX","CIK":"1438533","name":"TRAVERE THERAPEUTICS, INC.","OfficialName":"Travere Therapeutics Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1905907401.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210506"}]